Compare ADMA Biologics Inc (ADMA) vs iShares MSCI Japan ETF (EWJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs iShares MSCI Japan ETF — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while iShares MSCI Japan ETF trades at $96.81. The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EWJ | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $96.97 |
52-Week Low | $7.60 | $77.93 |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
EWJ, the iShares MSCI Japan ETF, trades at $96.90, up 1.84% with a bullish technical signal from moving averages. Recent U.S.-Japan yen intervention and domestic economic stimulus efforts, including a food tax cut, are key drivers. The ETF's RSI_6 at 90.64 indicates overbought conditions, while support and resistance cluster near $96-$97.
Outlook is cautiously optimistic due to policy support and export benefits from yen strength, but risks include inflation pressures and tech sector volatility. The dividend of $0.50 scheduled for June 2026 adds income appeal, though current financial ratios are undisclosed, requiring scrutiny of underlying holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →
